There were 499 biotech startups in 2020, with a total investment of $417.6 million in research & development.
Statistics on biotechnology in Turkey will be released by the Turkish Statistical Institute (TUIK) in the early part of 2019.
A total number of companies that use biotechnology in their products or services has been compiled.
In addition, 499 businesses in Turkey were involved in biotechnology research and development last year, and 363 in 2019.
According to an analysis of their size groupings, there are 369 businesses with 1-9 employees and 67 companies with 10–49 employees in this sector.
37 startups with 50-249 people and 26 startups with more than 250 employees were involved in biotechnology operations in the United States.
Last year, “DNA/RNA” was the most commonly employed technology by biotechnology startups.
“Bioprocessing” and “tissue and cell culture engineering” approaches were the second and third most commonly employed interventions, respectively, with 261 interventions each.
41.3 per cent of the organisations that plan to use biotechnology in 2020 are involved in human health (other treatments).
Together with diagnostic and medicine delivery systems, etc.).
To accomplish these efforts, 32.9 per cent used agricultural biotechnology, while 24 per cent used human health technologies (using rDNA technology).
In 2020, there will be 302 biotechnology startups in the market.
Biotechnology is used in the development of 454 of the companies announcing an engagement in biotechnology activities.
A total of 426 enterprises and 415 organisations have already established processes that necessitate the use of biotechnology.
In 2020, startup research and development costs totalled 417 million 560,618 liras. In the preceding year, these costs came to 324 million, 462 thousand, and 31 pounds.
For financial and non-financial enterprises, biotechnology R&D expenditures accounted for 1.1 per cent of total R&D expenditures in 2019. However, in 2020, this rate was recorded at 1.17 per cent.
Only 47.7 per cent of 2,753 biotechnology workers were men, while 52.3 per cent were women.
16.2 per cent of employees have a doctorate, and 22.2 per cent have a master’s degree.
There is 36.4 per cent with a bachelor’s degree, 7.7 per cent with a university education, and 17.9 per cent with secondary or lower education.
60.9 per cent of biotech businesses cited “access to funding” as the biggest challenge to their research and development.
After that, “access to qualified human resources” comes in at 49.7 per cent, followed by “regulation requirements” at 34.3 per cent.
For biotechnology goods to be commercialised, the main challenge was “international market access” (57.5 per cent).
to say nothing of the regulatory requirements (53.9%) or the lack of financial resources (24.9%). (53.5 per cent).